<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bayesian Event-Based Model for Disease Subtype and Stage Inference - Health AI Hub</title>
    <meta name="description" content="This paper introduces BEBMS, a novel principled Bayesian event-based model, designed to accurately infer disease subtypes and progression stages in chronic cond">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Bayesian Event-Based Model for Disease Subtype and Stage Inference</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.03467v1" target="_blank">2512.03467v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Hongtao Hao, Joseph L. Austerweil
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.ME
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.03467v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.03467v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces BEBMS, a novel principled Bayesian event-based model, designed to accurately infer disease subtypes and progression stages in chronic conditions characterized by structured heterogeneity. The study demonstrates that BEBMS significantly outperforms the widely used SuStaIn model across synthetic data experiments with varying misspecification levels, and yields results more consistent with scientific consensus when applied to real-world Alzheimer's disease data.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant for personalized medicine as it provides more accurate and robust tools to identify distinct disease subtypes and stages. Such precision can lead to better tailored diagnostics, prognostics, and targeted therapeutic interventions for patients with complex chronic diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper presents a Bayesian machine learning model (BEBMS) designed to infer disease subtypes and progression stages from patient data, particularly cross-sectional data. This is an AI application that aims to improve the understanding of how diseases, like Alzheimer's, progress in different patient groups, potentially leading to better diagnostic tools, prognostic indicators, and personalized treatment approaches. It acts as an advanced analytical tool for medical data interpretation.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Chronic diseases often exhibit structured heterogeneity, progressing via a small number of distinct subtypes rather than random variation.</li>
                    
                    <li>The existing SuStaIn (Subtype and Stage Inference Event-Based Model) is widely used to estimate disease subtypes, progression order for each, and patient assignment from cross-sectional data, but its robustness is a concern.</li>
                    
                    <li>The authors developed BEBMS (Bayesian subtype variant of the event-based model), a new principled Bayesian approach, to address these challenges with improved robustness.</li>
                    
                    <li>BEBMS's performance was rigorously compared against SuStaIn using a variety of synthetic datasets, systematically varying levels of model misspecification.</li>
                    
                    <li>BEBMS substantially outperformed SuStaIn across critical evaluation tasks, including the accuracy of event ordering, patient staging, and subtype assignment.</li>
                    
                    <li>When applied to a real-world Alzheimer's disease dataset, BEBMS produced results that were found to be more consistent with the established scientific understanding of Alzheimer's progression compared to SuStaIn.</li>
                    
                    <li>The work aims to provide a more robust and accurate computational tool for uncovering the underlying structure of disease progression, which is vital for understanding and managing heterogeneous diseases.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved the development of BEBMS, a novel principled Bayesian variant of the event-based model. Its performance was then comparatively evaluated against the established SuStaIn model. This evaluation utilized both diverse synthetic datasets designed to assess robustness under various model misspecifications, and a real-world Alzheimer's disease dataset to validate consistency with scientific consensus.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>BEBMS significantly outperforms SuStaIn in synthetic data experiments across tasks of ordering, staging, and subtype assignment. Furthermore, BEBMS yielded results for Alzheimer's disease that were more consistent with the current scientific consensus on disease progression compared to SuStaIn's findings.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The enhanced accuracy and robustness of BEBMS in identifying disease subtypes and stages hold significant clinical potential. It could enable earlier and more precise diagnosis, facilitate the development of subtype-specific treatments, refine prognostic predictions, and optimize patient stratification for clinical trials in complex, heterogeneous chronic conditions, such as Alzheimer's disease.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly mention any limitations of the BEBMS model or the study itself, focusing primarily on its superior performance and consistency.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state future research directions for the BEBMS model or its applications.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurodegenerative diseases</span>
                    
                    <span class="tag">Chronic diseases</span>
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Geriatrics</span>
                    
                    <span class="tag">Personalized medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Bayesian models</span>
                    
                    <span class="tag tag-keyword">disease subtypes</span>
                    
                    <span class="tag tag-keyword">disease progression</span>
                    
                    <span class="tag tag-keyword">event-based models</span>
                    
                    <span class="tag tag-keyword">SuStaIn</span>
                    
                    <span class="tag tag-keyword">Alzheimer's disease</span>
                    
                    <span class="tag tag-keyword">machine learning</span>
                    
                    <span class="tag tag-keyword">medical statistics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Chronic diseases often progress differently across patients. Rather than randomly varying, there are typically a small number of subtypes for how a disease progresses across patients. To capture this structured heterogeneity, the Subtype and Stage Inference Event-Based Model (SuStaIn) estimates the number of subtypes, the order of disease progression for each subtype, and assigns each patient to a subtype from primarily cross-sectional data. It has been widely applied to uncover the subtypes of many diseases and inform our understanding of them. But how robust is its performance? In this paper, we develop a principled Bayesian subtype variant of the event-based model (BEBMS) and compare its performance to SuStaIn in a variety of synthetic data experiments with varied levels of model misspecification. BEBMS substantially outperforms SuStaIn across ordering, staging, and subtype assignment tasks. Further, we apply BEBMS and SuStaIn to a real-world Alzheimer's data set. We find BEBMS has results that are more consistent with the scientific consensus of Alzheimer's disease progression than SuStaIn.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>32 pages; machine learning for health symposium (2025); Proceedings of the 5th Machine Learning for Health Symposium in PMLR</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>